We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Danish-based Veloxis Pharmaceuticals’ US subsidiary has signed two different exclusive licence, supply and distribution agreements to register, commercialise and distribute Envarsus XR in China (including Taiwan, China Region) and Canada.